Advertisement

Die Therapie der chronischen Virushepatitis — Ein noch ungelöstes Problem mit neuen Perspektiven

  • K. H. Wiedmann

Zusammenfassung

Die chronische Virushepatitis ist eine heterogene Erkrankung, die entweder durch das Hepatitis-B-Virus, das Hepatitis-Delta-Virus oder durch Non-A-non-B-Viren hervorgerufen werden kann. Die beiden ersten Formen sind aufgrund serologischer und molekularbiologischer Methoden eindeutig definiert, die Diagnose der Non-A-non-B-Hepatitis stellt bislang noch eine Ausschlußdiagnose dar und basiert hauptsächlich auf anamnestischen Angaben (Transfusionen, Gerinnungspräparate, Drogenabusus, epidemisches Auftreten), auch wenn sich hier möglicherweise ein Durchbruch in der serologischen Diagnostik durch den kürzlich gelungenen Nachweis von 2 der Non-A-non-B-Viren abzeichnet [8, 44]. Eine spezifische kausale Therapie der verschiedenen Formen der Virushepatitis gibt es bisher leider noch nicht. In den letzten Jahren ist aber etwas mehr Klarheit in die Therapiekonzepte dieser Erkran-kungen eingekehrt, und es zeichnen sich geringe Fortschritte ab. Diese sind eng mit den Fortschritten auf dem Gebiet der Virologie und der Aufklärung der Pathogenese der Hepatititen verknüpft, wie man besonders deutlich am Beispiel der Hepatitis-B-Infektion sehen kann.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aach RD, Lander JJ, Sherman LA et al. (1978) Transfusion-transmitted viruses: interim analysis of hepatitis among transfused and nontransfused patients. In: Vyas GN, Cohen SN, Schmid R (eds) Viral hepatitis. Franklin Inst Press, Philadelphia, pp 383 — 396Google Scholar
  2. 2.
    Aldershvile JO, Dietrichson P, Skinhoj et al. (1982) Chronic persistent hepatitis: serological classification and meaning of the hepatitis Be system. Hepatology 2: 243PubMedGoogle Scholar
  3. 3.
    Alexander GJM, BrahmJ, Fagan A, Smith HM, Daniels H, Eddieston ALWF, Williams R (1987) Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 11: 66 — 68Google Scholar
  4. 4.
    Alexander GJM, Fagan EA, Rolando N, Guarner P, Callender ME, Eddleston ALWF, Williams R (1986) Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection — A possible reason for lack of efficacy. J Hepatol 3 [Suppl 2]: 81 — 86Google Scholar
  5. 5.
    Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE (1981) Donor transaminase and recipient hepatitis: impact on blood transfusion services. JAMA 246: 630 — 634PubMedGoogle Scholar
  6. 6.
    Anderson MG, Harrison TJ, Alexander GJM, Zuckermann AJ, Murray-Lyon IM (1986) Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B. J Hepatol 3 [Suppl 2]: 225 — 227Google Scholar
  7. 7.
    Anderson MG, Murray-Lyon IM (1985) Natural history of the HBsAg carrier. Gut 26: 848 — 860PubMedGoogle Scholar
  8. 8.
    Arankalle VA, Ticehurst J, Sreenivasan MA, Kapikian AZ, Popper H, Pavri KM, Purcell H (1988) Aetiological association of a virus-like particle with enterically transmitted non-A, non-B hepatitis. Lancet 1: 550 — 554PubMedGoogle Scholar
  9. 9.
    Arrigoni A, Ponzetto A, Actis G et al. (1983) Levamisole and chronic delta hepatitis. Ann Intern Med 98: 1024PubMedGoogle Scholar
  10. 10.
    Bassendine MF, Weller IVD, Murray A, Summers J, Thomas HC, Sherlock S (1980) Treatment of HBsAg positive chronic liver disease with Bacillus Calmette Guerin (BCG). Gut 21: A 915Google Scholar
  11. 11.
    Beasley RP, Hwang L-Y, Lin CC et al. (1981) Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Lancet 2: 388 — 393PubMedGoogle Scholar
  12. 12.
    Bisceglie Di AM, Kassianidis C, Lisker-Melman M et al. (1987) Treatment of chronic type B hepatitis with recombinant human alpha and gamma interferon in combination: a dose-finding study. Hepatology 7: 1117Google Scholar
  13. 13.
    Bonino F, Rosina F, Rizzetto M et al. (1986) Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 90: 1268 — 1273PubMedGoogle Scholar
  14. 14.
    Bortolotti F, Cadrobbi P, Crivellaro C et al. (1981) Chronic hepatitis type B in children: longitudinal study of 35 cases. Gut 22: 499 — 504PubMedGoogle Scholar
  15. 15.
    Brechot C, Hadchovel M, Scotto J et al. (1981) Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet 2: 7765 — 7767Google Scholar
  16. 16.
    Brzosko WJ, Debski R, Derecka K (1978) Immunstimulation for chronic active hepatitis. Lancet 11: 311Google Scholar
  17. 17.
    Burrell CJ, Gowans EJ, Rowland R et al. (1984) Correlation between liver histology and markers of hepatitis B virus replication in infected patients: a study by in situ hybridization. Hepatology 4: 20 — 24PubMedGoogle Scholar
  18. 18.
    Cantell K, Hirvonen S, Mogensen KE et al. (1974) Human leucocyte interferons: production, purification, stability and animal experiments. The production and use of interferon for treatment of human virus infections. In Vitro 3: 35 — 38Google Scholar
  19. 19.
    Caredda F, Rossi E, D’Arminio Monforte A et al. (1985) Hepatitis B virus-associated coinfection and superinfection with A agent: indistinguishable disease with different outcome. J Infect Dis 151: 925 — 928PubMedGoogle Scholar
  20. 20.
    Caselmann H, Eisenburg J, Hofschneider PH, Koshy R (1987) Antiviral therapy of chronic active hepatitis B with interferon beta and -gamma: a controlled trial. J Med Virol 21:128 AGoogle Scholar
  21. 21.
    Chadwick RG, Bassendine MF, Crawford E et al. (1978) HBs antigen positive chronic liver disease inhibition of DNA polymerase activity by vidarabine. Br Med J 2:531 — 537PubMedGoogle Scholar
  22. 22.
    Chu C, Karayannis P, Fowler MJF et al. (1985) Natural history of chronic hepatitis B virus infection in Taiwan. Studies of hepatitis B virus DNA in serum. Hepatology 3: 431Google Scholar
  23. 23.
    Conn H, Maddrey WC, Soloway RJ (1982) The detrimental effects of adrenocortico-steroid therapy in HBsAg-positive chronic active hepatitis: fact or artifact? Hepatology 2: 885 — 887PubMedGoogle Scholar
  24. 24.
    Czaja AJ, Wolf AM (1977) Steroid treatment of HBsAg-positive severe chronic active liver disease: determinants of early prognosis. Gastroenterology 73: 19Google Scholar
  25. 25.
    Davis GL, Hoofnagle JH, Waggoner JG (1984) Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 86: 230 — 235PubMedGoogle Scholar
  26. 26.
    Davis GL, Hoofnagle JH (1986) Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology 10:38— 1041Google Scholar
  27. 27.
    De Grote J, Fevery J, Lepontre L (1978) Long term follow up of chronic active hepatitis of moderate severity. Gut 19: 510 — 513Google Scholar
  28. 28.
    De Man RA, Schalm WS, Heytink RA et al. (1987) Interferon plus Descyclovir in chronic hepatitis type B: incidence of virus marker elimination and reactivation. J Med Virol 21:120 AGoogle Scholar
  29. 29.
    Desmyter J, Ray MB, Groote de J et al. (1976) Administration of human fibroblast Interferon in chronic hepatitis B infection. Lancet 11: 645 — 646Google Scholar
  30. 30.
    Dienstag JL (1983) Non-A, non-B hepatitis I. Recognition, epidemiology, and clinical features. Gastroenterology 85: 439 — 462PubMedGoogle Scholar
  31. 31.
    Dienstag JL, Alter H J (1986) Non-A, non-B hepatitis. Evolving epidemiologic and clinical perspective. Gen Liver Dis 6: 67 — 81Google Scholar
  32. 32.
    Dienstag JL, Stevens CE, Bhan AK, Szmuness W (1982) Hepatitis B vaccine adminis¬tered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 96: 575 — 579PubMedGoogle Scholar
  33. 33.
    Doherty PC, Zinkernagel RM (1975) A biological role for major histocompatibility antigens. Lancet 1: 1406 — 1409PubMedGoogle Scholar
  34. 34.
    Dolen JG, Carter WA, Horoszewicz JS, Vladutiu AO, LeibowitzAI, Nolan JP (1979) Fibroblast interferon treatment of a patient with chronic active hepatitis. Am J Med 67: 127 — 131PubMedGoogle Scholar
  35. 35.
    DooleyJS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH (1986) Pilot study of recombinant human alphainterferon for chronic type B hepatitis. Gastroenterology 90: 150 — 157PubMedGoogle Scholar
  36. 36.
    Drüeke T, Barbanel C, Jungers P et al. (1980) Hepatitis B antigen-associated periarteritis nodosa in patients undergoing long-term hemodialysis. Am J Med 68: 86 — 90PubMedGoogle Scholar
  37. 37.
    Dudley FJ, Scheuer PJ, Sherlock S (1972) Natural history of hepatitis associated antigen positive chronic liver disease. Lancet 11: 1388 — 1393Google Scholar
  38. 38.
    Dusheiko GM, Paterson AC, Pitcher L, Kassianides C, Biscegli Di AM, Song E, Kew MC (1986) Recombinant leucocyte interferon treatment of chronic hepatitis B — an analysis of two therapeutic trials. J Hepatol 3 [Suppl 2]: 199 — 207Google Scholar
  39. 39.
    Edy VG, Billiau A, De Sommer P (1976) Human fibroblast and leukocyte interferons show different dose-response curves in assay of cell protection. J Gen Virol 31:251 —255Google Scholar
  40. 40.
    Eisenberg M, Rosno S, Garcia G, Konrad MW, Gregory PB, Robinson S, Merigan TC (1986) Preliminary trial of recombinant fibroblast Interferon in chronic hepatitis B virus infection. Antimicrob Agents Chemother 29: 122 — 126PubMedGoogle Scholar
  41. 41.
    Elion B (1982) Mechanism of action and selectivity of Acyclovir. Am J Med 73:1 A, 7—13Google Scholar
  42. 42.
    Esteban R, Buti M, Vallès M, Allende H, GuardiaJ (1986) Hepatitis B-associated membranous glomerulonephritis treated with adenine arabinoside monophosphate. Hepatology 6: 762 — 764Google Scholar
  43. 43.
    European Association for the Study of the Liver (Trial Group) (1986) Steroids in chronic B-hepatitis. A randomized, double-blind, multinational trial on the effect of low-dose. Longterm treatment of survival. Liver 6: 227 — 232Google Scholar
  44. 44.
    Ezzel C (1988) Candidate cause identified of non-A, non-B hepatitis. Nature 333: 335Google Scholar
  45. 45.
    Farci P, Karayannis P, Smedile A et al. (1985) Chronic delta virus infection: response to lymphoblastoid interferon. J Hepatol [Suppl 2] 227Google Scholar
  46. 46.
    Fattovich G, Brullo L, Pontisso P et al. (1986) Laevamisole therapy in chronic type B hepatitis. Results of a double-blind randomized trial. Gastroenterology 91: 692 — 696PubMedGoogle Scholar
  47. 47.
    Franco A, Barnaba V, Levrero M, Ruberti G, Van Dyke A, Bonavita MS, Balsano F (1986) Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) adminis-tration on hepatitis B virus-related chronic liver disease. J Hepatol 3 [Suppl 2]: 239 — 243Google Scholar
  48. 48.
    Garcia G, Scullard G, Smith C et al. (1985) Preliminary observation of hepatitis B-associated membranous glomerulonephritis treated with leukocyte interferon. Hepatology 5: 317 — 320PubMedGoogle Scholar
  49. 49.
    Garcia G, Smith I, Weissberg I et al. (1987) Adenine arabinoside monophosphate (vi-darabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Ann Intern Med 107: 278 — 285PubMedGoogle Scholar
  50. 50.
    Giusti G, Piccinino F, Ruggiero G et al. (1977) Treatment of chronic active hepatitis with either prednisolone or corticothropin: a controlled trial. Acta Hepatogastro-enterol 24: 131 — 139Google Scholar
  51. 51.
    Gocke J, HsuK, Morgan C et al. (1970) Association between polyarteritis and Australia antigen. Lancet II: 1149 —1153Google Scholar
  52. 52.
    Gömez C, la Banda F, Porres JC et al. (1987) Combined recombinant alpha and gamma interferon treatment of chronic hepatitis B virus infection. J Med Virol 21:127 AGoogle Scholar
  53. 53.
    Gray PW, Goddel DV (1982) Structure of the human immune interferon. Gene Nature (Lond) 298: 859Google Scholar
  54. 54.
    Greenberg HB, Pollard RB, Lutwick LI et al. (1976) Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295: 517 — 522PubMedGoogle Scholar
  55. 55.
    Gudat F, Bianchi L, Sonnabend W, Theil G, Aenishaenslin W, Stalder GA (1975) Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. Lab Invest 32: 1 — 5PubMedGoogle Scholar
  56. 56.
    Hadziyannis SJ, Liberman HM, Karvountzes GG, Shafritz DA (1983) Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg versus Anti-HBe positive carriers of hepatitis B virus. Hepatology 3: 656 — 662PubMedGoogle Scholar
  57. 57.
    Havell EA, Yip YK, Vilcet J (1977) Characteristics of human lymphoblastoid (Namalva) interferon. J Gen Virol 38: 51 — 53Google Scholar
  58. 58.
    Hess G, Gerlich W, Gerken G, Manns M, Hütteroth T, Meyer zum Büschenfelde KH (1987) The effect of recombinant interferon treatment on serum levels of hepatitis B virus-encoded proteins in man. Hepatology 7: 704 — 708PubMedGoogle Scholar
  59. 59.
    Hess G, Gerlich W, Weber C, Drees N, Meyer zum Büschenfelde KH (1987) Treatment of chronic type B hepatitis with recombinant leucocyte alpha A interferon: results of a phase II trial. J Med Virol 21:123 AGoogle Scholar
  60. 60.
    Hoofnagle JH (1982) Chronic hepatitis: The role of corticosteroids. In: Szmuness W, Alter HJ, Maynard JE (eds) Viral hepatitis. Franklin Inst Press, Philadelphia, p 573Google Scholar
  61. 61.
    Hoofnagle JH, Davis GL, Pappas SC et al. (1986) A short course of prednisolone in chronic type B hepatitis. Ann Intern Med 104: 12 — 17PubMedGoogle Scholar
  62. 62.
    Hoofnagle JH, Dusheiko GM, Seeff LB (1981) Seroconversion from hepatitis Be antigen to antibody in chronic type B hepatitis. Ann Intern Med 94: 744 — 748PubMedGoogle Scholar
  63. 63.
    Hoofnagle JH, Hanson RG, Minuk GY et al. (1984) Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86: 150 — 157PubMedGoogle Scholar
  64. 64.
    Hoofnagle JH, Mullen KD, Junes D et al. (1986) Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315: 1575 — 1578PubMedGoogle Scholar
  65. 65.
    Hoofnagle JH, Peters MG, Muller DK et al. (1985) Randomised controlled trial of a four-month course of recombinant human alpha interferon in chronic type B hepatitis. Hepatology 5: 1033Google Scholar
  66. 66.
    Hoofnagle JH, Seef LB, Bales ZM et al. (1978) Serologic responses in hepatitis B. In: Vyas GN, Cohen SN, Schmid R (eds) Viral hepatitis. Franklin Inst Press, Philadelphia, pp 219 — 241Google Scholar
  67. 67.
    Hoofnagle JH, Shafritz DA, Popper H (1987) Chronic type B hepatitis and the “healthy” HBsAg carrier state. Hepatology 7: 758 — 763PubMedGoogle Scholar
  68. 68.
    Hoofnagle JH, Smedile A, Mullen K et al. (1985) Treatment of chronic delta hepatitis with recombinant human alpha interferon. Gastroenterology 88: 1665Google Scholar
  69. 69.
    Hütteroth TH, Arnold W, Hopf U, Meyer zum Büschenfelde KH (1978) Zirkulierende Immunkomplexe bei akuter Virushepatitis, chronisch-aktiver Hepatitis und Periarteriitis nodosa. Gastroenterol 6: 395 — 402Google Scholar
  70. 70.
    Isaacs A, Lindenmann J (1957) Virus interference: the interferon. Proc R Soc Med 147: 258Google Scholar
  71. 71.
    Ikeda T, Lever AML, Thomas LC (1986) Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 6: 962 — 965PubMedGoogle Scholar
  72. 72.
    Kato Y, Nakogawa H, Kobayaski K et al. (1982) Interferon production by peripheral lymphocytes in HBsAg-positive liver diseases. Hepatology 2: 789 — 790PubMedGoogle Scholar
  73. 73.
    Kingham JGC, Ganguly NK, Shaari ZD et al. (1978) Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon. Gut 19: 91 — 94PubMedGoogle Scholar
  74. 74.
    Kirchner H (1986) Das Interferonsystem unter besonderer Berücksichtigung des Gamma-Interferons. Dtsch Med Wochenschr 111: 64 — 70PubMedGoogle Scholar
  75. 75.
    Kirchner H (1984) Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 7: 347–374PubMedGoogle Scholar
  76. 76.
    Kiyosawa K, Akahane Y, Nagata A et al. (1984) Hepatocellular carcinoma after non- A, non-B posttransfusion hepatitis. Am J Gastroenterol 79: 777 — 781Google Scholar
  77. 77.
    Kiyosawa K, Sodeyama S, Oike Y, Yoda H, Gibo Y, Koike Y, Furuta S (1987) Treatment of chronic non-A non-B hepatitis with interferon. J Med Virol 21:128 AGoogle Scholar
  78. 78.
    Koff RS, Galambos JT (1987) Viral hepatitis. In: Schiff L, Schiff ER (eds) Diseases of the liver, 6th edn. Lippincott, Philadelphia, pp 457 — 458fGoogle Scholar
  79. 79.
    Lam KC, Lai CL, Trepo C, Wu PC (1981) Deleterious effect of prednisolone in HBsAg- positive chronic active hepatitis. N Engl J Med 304: 380 — 386PubMedGoogle Scholar
  80. 80.
    Lengyel P (1981) Mechanisms of interferon action: the 25 A synthetase-RNase L path-way. In: Gresser I (ed) Interferon 3. Academic, New York, pp 77 — 99Google Scholar
  81. 81.
    Levin S, Hahn T (1982) Interferon system in acute viral hepatitis. Lancet 1: 592 — 594PubMedGoogle Scholar
  82. 82.
    Liaw YF, Chu CM, Su IH et al. (1983) Clinical and histological events preceding hepatitis Be antigen seroconversion in chronic types hepatitis. Gastroenterology 84:216— 219PubMedGoogle Scholar
  83. 83.
    Liaw YF, Lin DY, Chu CM et al. (1983) A prospective trial of prednisolone combined with azathioprine in HBsAg-positive chronic active hepatitis. Acta Hepatogastroenterol 30: 51 — 53Google Scholar
  84. 84.
    Lo KJ, Tong MJ, Chin ML et al. (1982) The natural history of hepatitis B surface antigen positive chronic liver disease in Taiwan. J Infect Dis 146: 205 — 210PubMedGoogle Scholar
  85. 85.
    Lok ASF, Hadziyannis SJ, Weller IVD, Karvountzis MG et al. (1984) Contribution of low level HBV replication to continuing inflammatory activity in patients with anti- HBe positive chronic hepatitis B virus infection. Gut 25: 1283 — 1287PubMedGoogle Scholar
  86. 86.
    Lok ASF, Lai CL, Wu PC (1987) Randomized controlled trial of recombinant alpha-2- interferon in chronic hepatitis B virus (HBV) infection. J Med Virol 21:121 AGoogle Scholar
  87. 87.
    Lok ASF, Novick DM, Karayiannis P, Dunk AA, Sherlock S, Thomas HC (1985) An randomized study of the effects of adenine arabinoside 5’-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 5: 1132 — 1138PubMedGoogle Scholar
  88. 88.
    Lok ASF, Weiler IVD, Karayiannis P et al. (1984) Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 4: 45 — 49PubMedGoogle Scholar
  89. 89.
    Lok ASF, Wilson LA, Thomas HC (1984) Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J Antimicrob Chemother 14: 93 — 99PubMedGoogle Scholar
  90. 90.
    MaierKP, BlumH, Gerok W et al. (1983) Correspondence. Hepatology 3: 130Google Scholar
  91. 91.
    McDonald JA, Caruso L, Karayiannis P, Scully LJ et al. (1987) Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 7: 719 — 723PubMedGoogle Scholar
  92. 92.
    Meyer zum Büschenfelde KH (1978) Immunsuppressive Therapie der HBs-Antigen positiven und negativen chronisch aktiven Hepatitis. Dtsch Med Wochenschr 103:887— 892Google Scholar
  93. 93.
    Miller RH, Robinson WS (1984) Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver. Virology 137: 390 — 399PubMedGoogle Scholar
  94. 94.
    Miyakawa H, Hino K, Iwasaki M et al. (1983) Combined therapy with prednisolone and adenine-arabinoside available for chronic hepatitis B. Hepatology 3: 1078Google Scholar
  95. 95.
    Mizushima N, Kanai K, Matsuda H et al. (1987) Improvement of proteinuria in a case of hepatitis B-associated glomerulonephritis after treatment with interferon. Gastroenterology 92: 524 — 526PubMedGoogle Scholar
  96. 96.
    Möller B, HopfU, SieberG, Rosenkranz K, Poeschke S, SiegertW (1987) Treatment of heterosexual and homosexual patients with HBeAg positive chronic hepatitis B with low dose interferon alpha (IFn-A). Hepatology 7: 1148Google Scholar
  97. 97.
    Mondelli M, Mieli-Vergani G, Alberti A et al. (1982) Specificity of T-lymphocyte cyto-toxicity to autologous hepatocytes in chronic HBV infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129:2773— 2778PubMedGoogle Scholar
  98. 98.
    Montano L, Miescher GC, Goodall AH, Wiedmann KH, Janossy G, Thomas HC (1982) Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology 2: 557 — 561PubMedGoogle Scholar
  99. 99.
    Müller R, Vido I, Siegert W, Wöltje M, Klein H, Staar U, Schmidt FW (1980) Exogenes interferon in chronic hepatitis B infection. In: Biandi L, Gerok W, Sickinger K, Stalder GA (eds) Virus and the liver. MTP Press, Lancaster, p 355Google Scholar
  100. 100.
    Müller R, Klein H, Vido I, Niehoff G, Lautz HU, Gebel M, Schmidt FW (1986) Antiviral treatment in chronic hepatitis B - data of 5 prospectively controlled randomized trials. J Hepatol 3 [Suppl 2]: 217 — 223Google Scholar
  101. 101.
    Müller R, Vido I, Schmidt FW (1981) Rapid withdrawal of immunsuppressive therapy in chronic active hepatitis B infection. Lancet 1: 1323PubMedGoogle Scholar
  102. 102.
    Müller R, Deinhardt F, Hofschneider HP et al. (1982) Long term treatment with human fibroblast interferon in chronic hepatitis B: preliminary data of a controlled trial. In: Szmuness W, Alter HJ, Maynard JE (eds) Viral hepatitis. Franklin Inst Press, Philadelphia, pp 648 — 649Google Scholar
  103. 103.
    Nagashima H, Armia T, Suzuki H et al. (1987) Treatment of chronic non-A, non-B hepatitis with human interferon?. J Med Virol 31:128 AGoogle Scholar
  104. 104.
    Nagata S, Mantei N, Weissmann C (1980) The structure of one of the eight or more distinct chromosomal genes for human interferon-Alpha. Nature 287: 041Google Scholar
  105. 105.
    Nair PV, Tong MJ, Stevenson D (1986) A pilot study on the effects of prednisone withdrawal on serum HBV-DNA and HBeAg in chronic active hepatitis B. Hepatology 6: 1319 — 1324PubMedGoogle Scholar
  106. 106.
    Nilius R, Schentke U, Otto L et al. (1983) Levamisole therapy in chronic hepatitis - results of a multicenter double blind trial. Hepatogastroenterol 30: 90 — 92Google Scholar
  107. 107.
    Novick DM, Lok ASF, Thomas HC (1984) Diminished resonsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J Hepatol 1:29— 35Google Scholar
  108. 108.
    Omata M, Imazeki F, Yokoguka O et al. (1985) Recombinant leukocyte A interferon treatment in patients with chronic hepatitis B virus infection. Gastroenterology 88: 870 — 880PubMedGoogle Scholar
  109. 109.
    Omata M, Yokosuka O, Imazeki F, Okunda K (1984) Combined steroid withdrawal and anti-viral agent in the treatment of HBeAg positive patients. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune & Stratton, New York, p 670Google Scholar
  110. 110.
    OuzanD, Degos F, Marcellin P, Chevallier M, Degott C, Berthelot P, BenhamouJP (1987) Vidarabin treatment of chronic active hepatitis associated with hepatitis B virus replication a multicenter randomized controlled study. J Med Virol 21:124 AGoogle Scholar
  111. 111.
    Ouzan D, Trepo C (1986) Étude de la réplication virale et des manifestations hépatiques dans sept cas de périartérite noueuse associés au virus l’hépatite B. Gastroenterol Clin Biol 10: 53 — 56PubMedGoogle Scholar
  112. 112.
    Pappas SC, Hoofnagle JH, Young N et al. (1985) Treatment of chronic non-A non-B hepatitis within Acyclovir: pilot study. J Med Virol 15: 1 — 9PubMedGoogle Scholar
  113. 113.
    Perrillo R, Regenstein F, Peters M, Bodicky C, Campbell C (1987) A randomized, con-trolled trial of prednisone withdrawal followed by recombinant alpha interferon (rlFN- alpha) in the treatment of chronic hepatitis B. J Med Virol 21:124 AGoogle Scholar
  114. 114.
    Perrillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5’monophosphate and prednisone withdrawal followed by adenine arabinoside 5’monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780 — 786PubMedGoogle Scholar
  115. 115.
    Peters M, Davis GL, Dooley J, Hoofnagle JH (1986) The interferon system in acute and chronic viral hepatitis. Prog Liver Dis 8: 453 — 467PubMedGoogle Scholar
  116. 116.
    Pignatelli M, Waters J, Brown D et al. (1986) HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology 6: 349 — 353PubMedGoogle Scholar
  117. 117.
    Pignatelli M, Waters J, Thomas HC (1985) Evidence that cytotoxic T cells sensitized to HBe are responsible for hepatocyte lysis in chronic hepatitis B virus infection. Hepatology 5: 988Google Scholar
  118. 118.
    Pirovino M, Aguet M, Huber M et al. (1986) Absence of detectable serum interferon in acute and chronic viral hepatitis. Hepatology 6: 645 — 647PubMedGoogle Scholar
  119. 119.
    Poitrine A, Chousterman S, Chousterman M et al. (1985) Lack of in vivo activation of the interferon system in HBsAg-positive chronic active hepatitis. Hepatology 5:171— 174PubMedGoogle Scholar
  120. 120.
    Rakela J, Redeker AG, Welicky B (1983) Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 84: 956 — 960PubMedGoogle Scholar
  121. 121.
    Realdi G, Alberti A, Rugge M et al. (1982) Long-term follow-up of acute and chronic non-A, non-B posttransfusion hepatitis: evidence of progression to liver cirrhosis. Gut 23: 270PubMedGoogle Scholar
  122. 122.
    Realdi G, Alberti A, Rugge M et al. (1980) Seroconversion from hepatitis B “e” antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 79: 195 — 199PubMedGoogle Scholar
  123. 123.
    Reed WD, Eddieston ALWF, Cullens H et al. (1973) Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis. Lancet 11: 1347 — 1351Google Scholar
  124. 124.
    Renoux G, Renoux M (1972) Antigenic competition and nonspecific immunity after a rickettsial infection in mice: restoration of antibacterial immunity by phenyl-imidothi- azole treatment. J Immunol 109: 761 — 765PubMedGoogle Scholar
  125. 125.
    Resnick RH, Stone K, Antonioli D (1983) Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 28: 908 — 911PubMedGoogle Scholar
  126. 126.
    Ribot S, Rothstein M, Goldblatt M et al. (1979) Duration of hepatitis B surface anti-genemia (HBsAg) in hemodialysis patients. Arch Intern Med 139: 178 — 180PubMedGoogle Scholar
  127. 127.
    Rizzetto M (1983) The delta agent. Hepatology 3: 729 — 737PubMedGoogle Scholar
  128. 128.
    Rizzetto M, Canese MG, Aricò S et al. (1977) Immunofluorescence detection of a new antigen-antibody system (delta/anti-delta) associated with hepatitis B virus in liver and serum of HBsAg carriers. Gut 18: 997 — 1003PubMedGoogle Scholar
  129. 129.
    Rizzetto M, Hoyer BH, Purcell RH et al. (1984) Hepatitis delta virus infection. In: Vyas GN (ed) Viral hepatitis and liver disease. Grune & Stratton, Orlando, pp 371 — 379Google Scholar
  130. 130.
    Rizzetto M, Shih JWK, Gocke DJ et al. (1979) Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet 2: 986 — 990PubMedGoogle Scholar
  131. 131.
    Rizzetto M, Verme G, Recchia S et al. (1983) Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunsuppressive treatment. Ann Intern Med 98: 437 — 441PubMedGoogle Scholar
  132. 132.
    Robinson WS, Clayton DA, Greenman RL (1974) DNA of a human hepatitis B candidate. J Virol 14: 384 — 391PubMedGoogle Scholar
  133. 133.
    Roda E, Viza D, Pizza G, Mastroroberto L et al. (1985) Transfer factor for the treatment of HBsAg-positive chronic active hepatitis. Proc Soc Exp Biol Med 178:468— 475PubMedGoogle Scholar
  134. 134.
    Rosina F, Saracco G, Bona P et al. (1987) Treatment of chronic delta hepatitis with alpha 2 recombinant interferon. J Med Virol 21:123 AGoogle Scholar
  135. 135.
    Rustgi V, Hoofnagle JH, Gerin JL et al. (1985) Hepatitis B virus markers in patients with acquired immunodeficiency syndrome. Ann Intern Med 102: 795 — 797Google Scholar
  136. 136.
    Sacks SL, Scullard GH, Pollard RB et al. (1982) Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother 21: 93 — 100PubMedGoogle Scholar
  137. 137.
    Sagar AD, Sehgal PB, Slate DL, Ruddle FH (1982) Multiple human a interferon genes. J Exp Med 156: 744PubMedGoogle Scholar
  138. 138.
    Sagnelli E, Piccinino F, Manzillo G et al. (1983) Effect of immunosuppressive therapy on HBsAg-positive chronic active hepatitis in relation to presence or absence of HBeAg and anti-HBe. Hepatology 3: 690 — 695PubMedGoogle Scholar
  139. 139.
    Sagnelli E, Manzillo G, Mai G et al. (1980) Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 11: 395 — 397Google Scholar
  140. 140.
    Schalm SK, Heijtink RA (1982) Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg positive chronic active hepatitis: results of a placebo versus interferon trial. Hepatology 2: 791 — 794PubMedGoogle Scholar
  141. 141.
    Schalm SW, Heijtink RA, v Blankenstein M, Vreugendhil A (1982) Hepatitis B vaccin as immunostimulant in HBsAg (+) chronic hepatitis: results of a double-blind randomized study. Hepatology 2: 750Google Scholar
  142. 142.
    Schalm SW, Heijtink RA, van Buuren HR, de Man RA (1985) Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet 11: 358 — 360Google Scholar
  143. 143.
    Schalm SW, Summerskill WHJ, Gittnick GL, Elveback LR (1976) Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 17: 781 — 786PubMedGoogle Scholar
  144. 144.
    Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS (1982) Antiviral treatment of chronic hepatitis B virusinfection: infections virus cannot be detected in patient serum after permanent responses to treatment. Hepatology 2: 39 — 49PubMedGoogle Scholar
  145. 145.
    Scullard GH, Alberti A, Wansbrough-Jones MH et al. (1979) Effects of human leucocyte interferon on hepatitis B virus replication and immune responses in patients with chronic hepatitis B infection. J Clin Lab Immunol 1: 277 — 282PubMedGoogle Scholar
  146. 146.
    Scullard GH, Andres LL, Greenberg HB et al. (1981) Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology 1: 228 — 232PubMedGoogle Scholar
  147. 147.
    Scullard GH, Pollard RB et al. (1981) Antiviral treatment of chronic hepatitis B virus infection: changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 143: 772 — 783PubMedGoogle Scholar
  148. 148.
    Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB (1981) Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987 — 991PubMedGoogle Scholar
  149. 149.
    Scully LJ, Lever AML, Yap I, Pignatelli M, Thomas HC (1986) Identification of factors influencing response rate to antiviral therapy of chronic hepatitis B virus infection — a review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies. J Hepatol 3 [Suppl 2]: 291 — 299Google Scholar
  150. 150.
    Seeff LB, Wright EC, Zimmermann HJ et al. (1978) Posttransfusion hepatitis 1973— 1975: a Veterans Administration cooperative study. In: Vyas GN, Cohen SN, Schmid R (eds) Viral hepatitis a contemporary assessment of etiology, epidemiology, pathogenesis, and prevention. Franklin Inst Press, Philadelphia, pp 371 — 381Google Scholar
  151. 151.
    Sehgal P, Tamm LM, Tamm I (1982) Interferon and its inducers. In: Came P, Caliguiri EL A (eds) Chemotherapy of viral infections. Springer, Berlin Heidelberg New York, p 205Google Scholar
  152. 152.
    Shafritz DA, Shouval D, Shermann HI et al. (1981) Integration of hepatitis B virus DNA into the genome of liver cells chronic liver disease and hepatocellular carcinoma: studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305: 1067 — 1073PubMedGoogle Scholar
  153. 153.
    Sherlock S (1988) Treatment of chronic viral hepatitis. J Hepatol 6: 113 — 115PubMedGoogle Scholar
  154. 154.
    Shi-Shan L, Chang-Fu L, Fu-Ying H, Chang-Xue Z (1982) Preparation and clinical use of HBsAg immune RNA. Lancet 1: 197 — 198PubMedGoogle Scholar
  155. 155.
    Smedile A, Dentico P, Zanetti A et al. (1981) Infection with the HBV associated delta (0) agent in HBsAg carriers. Gastroenterology 81: 992 — 997PubMedGoogle Scholar
  156. 156.
    Smedila A, Rizzetto M, Bonino F et al.. (1984) Serum delta-associated RNA (DAR) in chronic HBV carriers infected with the delta agent. In: Vyas GN (ed) Viral hepatitis and liver disease. Grune & Stratton, Orlando, p 613Google Scholar
  157. 157.
    Smith CI, Kitchen LW, Scullard GH et al. (1982) Vidarabine monophosphate and human leucocyte interferon in chronic hepatitis B infection. JAMA 247: 2261 — 2265PubMedGoogle Scholar
  158. 158.
    Smith CI, Scullard GH, Gregory PH, Robinson WS, MeriganTC (1982) Preliminary studies of acyclovir in chronic hepatitis B. Am J Med 73/IA:267—270PubMedGoogle Scholar
  159. 159.
    Smith CI, Weissberg J, Bernhardt L et al. (1983) Acute Dane particle suppression with recombinant leucocyte A interferon in chronic hepatitis B virus infection. J Infect Dis 148: 907 — 913PubMedGoogle Scholar
  160. 160.
    Sodomann CP, Maerker-Alzer G, Havemann K et al. (1979) Transfer factor (TF) treatment of patients with HBs-Ag-positive chronic active hepatitis. Klin Wochenschr 57: 893 — 903PubMedGoogle Scholar
  161. 161.
    Summers J (1981) The recently described animal virus models for human hepatitis B virus. Hepatology 1: 179 — 183PubMedGoogle Scholar
  162. 162.
    Summers J, Mason WS (1982) Replication of the genome of a hepatitis B like virus by reverse transcription of an RNA intermediate. Cell 29: 403 — 415PubMedGoogle Scholar
  163. 163.
    Summers J, O’Connell A, Millmann I (1975) Genome of hepatitis B virus: Restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 72: 4597 — 4601PubMedGoogle Scholar
  164. 164.
    Szmuness W, Harley EJ, Ikram H et al. (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 330: 833 — 841Google Scholar
  165. 165.
    Szmuness W, Harley EJ, Ikram H et al. (1978) Sociodemographic aspects of the epidemiology of hepatitis B. In: Vyas GN, Cohen SN, Schmid R (eds) Viral hepatitis. Franklin Inst Press, Philadelphia, pp 297 — 320Google Scholar
  166. 166.
    Tage-Jensen U, Aldershvile J, Schlichting P et al. (1985) Immunosuppressive treatment of HBsAg-positive chronic liver disease: significance of HBeAg. Hepatology 5: 47 — 49PubMedGoogle Scholar
  167. 167.
    Taniguchi T, Mantei N, Schwarzstein M et al. (1980) Human leucocyte and fibroblast interferons are structurally related. Nature 285: 547 — 549PubMedGoogle Scholar
  168. 168.
    Thomas HC (1986) Has immunology become important to hepatologists? Prog Liv Dis 3: 179 — 189Google Scholar
  169. 169.
    Thomas HC, Lok ASF (1984) The immunopathology of autoimmune and HBV induced chronic hepatitis. Semin Liver Dis 4: 36 — 46PubMedGoogle Scholar
  170. 170.
    Thomas HC, Montano L, Goodall A, deKonig R, Oladapo J, Wiedmann KH (1982) Immunological mechanisms in chronic hepatitis B infection. Hepatology 2: 116 — 121Google Scholar
  171. 171.
    Thomas HC, Pignatelli M, Lever AML (1986) Homology between HBV-DNA and a sequence regulation the interferon-induced antiviral system: possible mechanism of persistent infection. J Med Virol 19: 63 — 69PubMedGoogle Scholar
  172. 172.
    Thomas HC, Scully LJ, McDonald JA (1986) Lymphoblastoid and recombinant alpha- A interferon therapy of chronic hepatitis B virus infection — The Royal Free Hospital experience. J Hepatol 3 [Suppl 2]: 193 — 197Google Scholar
  173. 173.
    Thomson BJ, Doran M, Lever AML, Webster ADB (1987) Alpha-interferon therapy for non-A non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1: 539PubMedGoogle Scholar
  174. 174.
    Tiollais P, Pourcel C, Dejean A (1985) The hepatitis B virus. Nature 317: 489 - 495PubMedGoogle Scholar
  175. 175.
    Tong J, Liu S, Co RL (1987) Persistence of serum hepatitis B virus deoxyribonucleic acid in hepatitis B surface antigen-positive patients with chronic persistent hepatitis treated with prednisone. Gastroenterology 92: 862 — 866PubMedGoogle Scholar
  176. 176.
    Tong MJ, NystromJS, Redeker AG, Marshall GJ (1976) Failure of transfer factor therapy in chronic active type B hepatitis. N Engl J Med 295: 209 — 211PubMedGoogle Scholar
  177. 177.
    Trepo C, Hantz O, van Nieuwenhuyse A et al. (1983) Efficacité et tolérance de l’acyclovir sur la réplication du virus HB resonsable de l’hepatic chronique active. Gastroenterol Clin Biol 8 /2: 191Google Scholar
  178. 178.
    Trepo C, Ouzan D (1985) Successful therapy of Polyarteriitis due to hepatitis B virus by combination of plasma exchanges and adenine arabinoside therapy. Hepatology 5: 1022Google Scholar
  179. 179.
    Trepo C, Ouzan D, Fontanges T et al. (1986) Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV. J Hepatol 3 [Suppl 2]: 97 — 105Google Scholar
  180. 180.
    Trepo CG, Zumerman AJ, Bird RC (1974) The role of circulating hepatitis B antigen/ antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol 27: 863 — 868PubMedGoogle Scholar
  181. 181.
    Tur-Kaspa R, Burk RD, Shanl Y, Shafrik DA (1986) Hepatitis B virus contains a glucocorticoid responsive element. Proc Natl Acad Sci USA 83: 1627 — 1631PubMedGoogle Scholar
  182. 182.
    Viola LA, Barrison IG, Coleman JC, Paradinas FJ, Murray-Lyon IM (1981) The H Be antigen antibody-system and its relationship to clinical and laboratory findings in 100 chronic HBsAg carriers in Great Britain. J Med Virol 8: 169 — 175PubMedGoogle Scholar
  183. 183.
    Weck PK, Apperson S, May L, Stebbing N (1981) Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol 57: 233 — 237PubMedGoogle Scholar
  184. 184.
    Weimar W, Heijtink RA, Schalm SW et al. (1977) Fibroblast interferon in HBsAg- positive chronic active hepatitis. Lancet 11: 1282 — 1283Google Scholar
  185. 185.
    Weimar W, Heijtink RA, Schalm SW, Sellekens H (1979) Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis. Eur J Clin Invest 9: 151 — 154PubMedGoogle Scholar
  186. 186.
    Weller IVD, Carreno V, Fowler MJF et al. (1983) Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration. J Antimicrob Chemother 11: 223 — 231PubMedGoogle Scholar
  187. 187.
    Weiler IVD, Lok ASF, Mindel A et al. (1985) A randomized controlled trial of adenine arabinoside 5’-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 26: 745 — 751Google Scholar
  188. 188.
    Weiler IVD, Bassendine MF, Murray AK, CraxiA, Thomas HC, Sherlock S (1982) Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut 23:650— 655Google Scholar
  189. 189.
    Wu PC, Lai CL, Lam KC, Ho J (1982) Prednisolone in HBsAg positive chronic active hepatitis: histologic evaluation in a controlled prospective study. Hepatology 2:777— 783PubMedGoogle Scholar
  190. 190.
    WussowP, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-INF antibody titres during interferon therapy. Lancet 11: 635 — 636Google Scholar
  191. 191.
    Yokosuka O, Omata M, Imazeki F et al. (1985) Changes of hepatitis B virus DNA in liver and serum caused by recombinant leucocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 5: 728 — 734PubMedGoogle Scholar
  192. 192.
    Yokosuka O, Omata M, Imazeki F et al. (1985) Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. Gastroenterology 89: 246 — 251PubMedGoogle Scholar
  193. 193.
    Zachoval R, Abb J, Eisenburg J, Pape GR, Zachoval V, Deinhardt F, Paumgartner G (1985) Production of interferon alpha and interferon gamma by peripheral blood leucocytes from patients with chronic hepatitis type B and non-A, non-B. Hepatology 5: 973Google Scholar
  194. 194.
    Zoon KC, Arnheiter H (1984) Studies of the interferon receptors. Pharmacol Ther 24: 259 — 278PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • K. H. Wiedmann

There are no affiliations available

Personalised recommendations